COVID 19 vaccine
A COVID 19 vaccine is a biotechnology product to provide acquired immune against coronavirus disease. As of September 2020, 234 vaccine candidates are in development, although no candidate has completed clinical trials to prove its safety and efficacy.
According to the data released by WHO, Chinese experts said in a new study that a phase 2 trial of a COVID -19 vaccine candidates have found that the vaccine is now safe and is inducing an immune response to a larger population compared to phase 1 trial hence giving the go-ahead for phase 3 trial, said professor Fengcai Zhu from Jiang Province Center for disease control, China.
The University of Oxford has also confirmed that coronavirus vaccine ChAdOx1 nCoV-19 indicates no early concerns and produces a strong immune response. The University of Oxford reported that the trial involves more than 1000 healthy adult volunteers whose the vaccine provoked a T cell response within 28 days.
The Russian Defense Ministry together with Gamaleya Scientific Research Institute of Epidemiology and Microbiology said that it has completed clinical trials of COVID-19 vaccine with the participation of volunteers. Without exception, all volunteers who received the vaccine have received immunity from the coronavirus and felt fine.
Germany biometric company BioNTech and U.S. pharmaceutical corporation Pfizer announced that data from their experimental COVID-19 vaccine showed that it was safe and induced an immune response and high level T cell response against the novel coronavirus in patients.
In a study published July 14 ,researchers reported that the COVID-19 vaccine MRNa-1273,co-developed by U.S National Institute of Allergy and Infectious Diseases and U.S. biotech firm Moderna Therapeutics, induced immune responses and no serious side effects in volunteers in the second clinical trial.